Cuprina Holdings (Cayman) Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $38.8K+9.2% YoYTTM through 31 Dec 2025
Net Income -$3.6MTTM through 31 Dec 2025
Free Cash Flow -$7.1MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | -1.3% |
| Operating Margin | -9,680.1% |
| Net Margin | -9,366.7% |
Returns
-92.4%ROE
-55.0%ROA
Balance Sheet Health
Debt / Equity0.68x
Current Ratio2.35x
Net Debt-$3Mnet cash position
Cash & Equivalents$2.4M
Quality Metrics
Altman Z-Score0.33
Piotroski F-Score2 / 9
FCF Margin-18,423.3%
Multi-Year Trend
RevenueFY2025: $49.9K
Diluted EPS-$1.42TTMFY2025: $-0.23
Dividend
No dividend
Capital Allocation
Capex Intensity116.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Maggot Debridement Therapy Product (MDT) | View detailsExpected to expand commercialization following FDA 510(k) clearance in June 2026 and regulatory milestones in Saudi Arabia. | ||
| Cosmeceutical Product | View detailsFocuses on health and beauty applications alongside core wound care therapies. |
Financials converted at 1.2839 from SGD.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.